

Electronic Supplementary Information

**HDAC Inhibitor Conjugated Polymeric Prodrug Micelles for
Doxorubicin Delivery**

Suchithra A. Senevirathne,^a Katherine E. Washington,^a Jason B. Miller,^b Michael C.

*Biewer,^a David Oupicky,^c Daniel J. Siegwart^{*b} and Mihaela C. Stefan^{*a}*

^aDepartment of Chemistry, University of Texas at Dallas, Richardson, TX, USA.

*Email: mihaela@utdallas.edu.

^bSimmons Comprehensive Cancer Center, Department of Biochemistry, University of
Texas Southwestern Medical Center, Dallas, TX, USA.

*E-mail: daniel.siegwart@utsouthwestern.edu

^cCenter for Drug Delivery and Nanomedicine, Department of Pharmaceutical
Sciences, University of Nebraska Medical Center, Omaha, USA




Figure S1. ¹H NMR of 4-hydroxycyclohexyl-4-phenylbutanoate




Figure S2. ^{13}C NMR of 4-hydroxycyclohexyl-4-phenylbutanoate




Figure S3. ^1H NMR of 4-oxocyclohexyl-4-phenylbutanoate




Figure S4. ^{13}C NMR of 4-oxocyclohexyl-4-phenylbutanoate




Figure S5. HSQC of 4-oxocyclohexyl-4-phenylbutanoate




Figure S6. ¹H NMR of γ -Phenylbutyrate- ϵ -Caprolactone




Figure S7. ¹³C NMR of γ -Phenylbutyrate- ϵ -Caprolactone




Figure S8. HSQC of γ -Phenylbutyrate- ϵ -Caprolactone




Figure S9. ^1H NMR of P1




Figure S10. ^1H NMR of P2